Principles of maintenance therapy

Leukemia Research

Volumn 30, Issue SUPPL. 1, 2006, Pages

  Berinstein, Neil L ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Maintenance therapy; Mechanisms; Minimal residual disease; Pharmacokinetics; Rituximab

Indexed keywords

CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFUSION RELATED REACTION; LYMPHOCYTOMA; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; ANIMAL; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, FOLLICULAR; RANDOMIZED CONTROLLED TRIALS;

EID: 33745920172     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(06)80002-0     Document Type: Article

References (45)

1. Gribben J.G., Neuberg D., Freedman A.S., Gimmi C.D., Pesek K.W., Barber M., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81 (1993) 3449-3457
2. Freedman A.S., Neuberg D., Mauch P., Soiffer R.J., Anderson K.C., Fisher D.C., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
3. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
4. Schouten H., Qian W., Kvaloy S., Porcellini A., Hagberg H., Johnson H.E., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
5. Lenz G., Dreyling M., Schiegnitz E., Haferlach T., Hasford J., Unterhalt M., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
6. Marcus R., Imrie K., Belch A., Cunningham D., Flores E., Catalano J., et al. CVP chemotherapy plus rituximab compared with CVP as firstline treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
7. Forstpointner R., Dreyling M., Repp R., Hermann S., Hanel A., Metzner B., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 3064-3071
8. (Abstract 060). Herold M., Pasold R., Stock S., Neser S., Niederwieser D., Neubauer A., et al. Rituximab plus mitoxantrone, chlorambucil, prednisolone (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma - results of a phase III study (OSHO39). Ann Oncol 16 Suppl 5 (2005) v51-v52
9. (Abstract 061). Hagenbeek A., Van Glabbeke M., Teodorovic I., Rozewicz C., Klasa R., Marcus R.E., et al. The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial. Ann Oncol 16 Suppl 5 (2005) v52
10. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106 (2005) 3725-3732
11. (Abstract 253). Hiddemann W., Dreyling M., Forstpointner R., Kneba M., Schmitz N., Schmits R., et al. Combined immunochemotherapy (R-CHOP) has a long lasting impact on subsequent consolidation in remission in follicular lymphoma but not in mantle cell lymphoma. Ann Oncol 6 (2005) v111
12. Hiddemann W., Griesinger F., and Unterhalt M. Interferon alfa for the treatment of follicular lymphomas. Cancer J Sci Am 4 Suppl 2 (1998) S13-S18
13. Rohatiner A., Radford J., Deakin D., Earl H., Love S.B., Price O., et al. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 85 (2001) 29-35
14. Lynch J.W., Hei D.L., Braylan R.C., Rimzsa L.M., Staab E.V., Bewsher C.J., et al. Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-Hodgkin's lymphoma. Am J Clin Oncol 25 (2002) 391-397
15. Aviles A., Neri N., Huerta-Guzman J., Perez F., and Sotelo L. Interferon alpha 2b as maintenance therapy improves outcome in follicular lymphoma. Leuk Lymphoma 45 (2004) 2247-2251
16. (Abstract 160). Salles G.A., Foussard C., Mounier M., Morschhauser F., Doyen C., Lamy T., et al. Rituximab added to IFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 104 (2004) 49a
17. Rohatiner A.Z., Gregory W.M., Peterson B., Borden E., Solal-Céligny P., Hagenbeek A., et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23 (2005) 2215-2223
18. Solal-Céligny P., Lepage E., Brousse N., Tendler C.L., Brice P., Haioun C., et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 23 (2005) 2215-2223
19. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma- a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1088-1095
20. (Abstract 6502). Hochster H.S., Weller E., Ryan T., Habermann T.M., Gascoyne R., Frankel S.R., et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23 (2004) 556
21. Ghielmini M., Schmitz S.-F.H., Cogliatti S.B., Pichert G., Hummerjohann J., Waltzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 103 (2004) 4416-4423
22. (Abstract 6527). Hiddemann W., Forstpointner R., Dreyling M., Gramatzki M., Böck H., Haenel M., et al. Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23 (2005) 566s
23. (Abstract 2535). Maloney D.G., Smith B., and Appelbaum F.R. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 88 (1996) 637a
24. Golay J., Zaffaroni L., Vaccad T., Lazzari M., Borleri G.-M., Bernasconi S., et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
25. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbuiet T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98 (2001) 3383-3389
26. Golay J., Manganini M., Facchinetti V., Gramigna R., Broady R., Borleri G., et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88 (2003) 1002-1012
27. van der Kolk L.E., de Haas M., Grillo-López A.J., Baars J.W., and van Oers M.H.J. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16 (2002) 693-699
28. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171 (2003) 1581-1587
29. Gluck W.L., Hurst D., Yuen A., Levine A.M., Dayton M.A., Gockerman J.P., et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10 (2004) 2253-2264
30. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99 (2002) 1038-1043
31. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., and Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99 (2002) 1314-1319
32. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7 (2001) 709-723
33. Alas S., Ng C.P., and Bonavida B. Rituximab modifies the cisplatinmitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin Cancer Res 8 (2002) 836-845
34. Jazirehi A.R., Huerta-Yepez S., Cheng G., and Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 65 (2005) 264-276
35. Maloney D.G. Mechanism of action of rituximab. Anticancer Drugs 12 Suppl 2 (2001) S1-S4
36. Berinstein N.L., Grillo-Lopez A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., et al. Association of serum Rituximab (IDEC-C2138) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998) 995-1001
37. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
38. Gordan L., Grow W.B., Pusateri A., Douglas V., Mendenhall N.P., and Lynch J.W. A phase 11 trial of individualized pharmacokinetic dosing of rituximab maintenance for patients with CD-20 positive lymphoproliferative disorders. J Clin Oncol 23 (2005) 1096-1102
39. Hainsworth J.D., Litchy S., Burris III H.A., Scullin Jr. D.C., Corso S.W., Yardley D.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
40. (Abstract 349). Hochster H.S., Weller E., Gascoyne R.D., Ryan T.S., Habermann T.M., Gordon L.I., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 Phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 (2005) 106a
41. (Abstract 353) [updated in oral presentation]. van Oers M.H.J., Van Glabbeke M., Teodorovic I., Rozewicz C., Klasa R., Marcus R.E., et al. Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed resistant follicular non-Hodgkin's lymphoma: final analysis of a phase III randomized intergroup clinical trial. Blood 106 (2005) 107a
42. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 655-661
43. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Parket K., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
44. Ghielmini M., Rufibach K., Salles G., Leoncini-Franscini L., Léger-Falandry C., Cogliatti S., et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16 (2005) 1675-1682
45. (Abstract 210). Horning S., Weller E., Hochster H., Frankel S., Gascoyne R., et al. B lymphocyte recovery in E1496: CVP +/- maintenance rituximab. Ann Oncol 16 (2005) v98